LY3114062 SC + Placebo + LY3114062 IV
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammatory Arthritis
Conditions
Inflammatory Arthritis
Trial Timeline
Jun 1, 2014 → Jun 1, 2015
NCT ID
NCT02144272About LY3114062 SC + Placebo + LY3114062 IV
LY3114062 SC + Placebo + LY3114062 IV is a phase 1 stage product being developed by Eli Lilly for Inflammatory Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02144272. Target conditions include Inflammatory Arthritis.
What happened to similar drugs?
10 of 20 similar drugs in Inflammatory Arthritis were approved
Approved (10) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02144272 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammatory Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 50 |
| CT-P13 | Celltrion | Phase 3 | 36 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 22 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 47 |
| fidaxomicin | Astellas Pharma | Approved | 43 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 39 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 29 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 42 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 35 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 39 |
| MORF-057 | Eli Lilly | Phase 2 | 35 |
| LY3009104 | Eli Lilly | Phase 1 | 29 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| Risankizumab | AbbVie | Approved | 43 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 36 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 29 |
| Human Papillomavirus Vaccine | Merck | Approved | 43 |
| Pembrolizumab | Merck | Phase 2 | 31 |
| Gardasil vaccine | Merck | Pre-clinical | 26 |
| Bezlotoxumab | Merck | Approved | 35 |